icon-folder.gif   Conference Reports for NATAP  
 
 

AASLD

The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
 
 
 
Single Dose Safety, Tolerability and Pharmacokinetics of AB-423 in Healthy Volunteers from the ongoing Single and Multiple Ascending Dose Study AB-423-001
 
 
  Reported by Jules Levin
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
 
Timothy Eley1, Sofia Caamano1, Jill Denning1, Karen Sims1, Richard Larouche2, William Symonds1, Patricia Mendez1 1Arbutus Biopharma Corporation, Burnaby, BC, Canada. 2.InVentiv Health, Quebec, QC, Canada

1110171

1110172

1110173

1110174

1110175

1110176

1110177